Background for Promotions.png

WEBINAR 

Applications of Multiplex Immunofluorescence for Immune Biomarkers in Drug Development

Immune infiltration in the tissue microenvironment is a hallmark of many disease indications, including cancer, autoimmune disease, degenerative conditions and others. Monitoring changes in immune heterogeneity according to disease state, or treatment with a drug is critical to understanding disease etiology and predicting response to treatments.

The multiple cell phenotypes of immune cells can be interrogated simultaneously on the same formalin-fixed paraffin-embedded (FFPE) section using multiplex immunohistochemistry (m-IHC). As such, multiplex immunofluorescence (m-IF) assays have become an established approach to measure immune biomarkers, from early discovery to exploratory endpoint testing in clinical trials. Despite the high utility of these assays in understanding mechanisms of disease, development and optimization is difficult due to the high complexity and need for deep domain and technical expertise, from staining to whole slide fluorescent imaging and analysis.

In this webinar, the speakers will:

  • Review the current challenges using these approaches encountered in biomarker discovery and development programs
  • Explain how using a combination of multiplex immunostaining and multispectral image analysis approaches can uncover insights needed to accelerate the development of tailored therapies

 

Speaker information below.

 

 

Access On-Demand Webinar Below:

About The Speakers

Joseph Krueger, Ph.D.
VP of Research & Applications, Advanced Pathology Services

Dr. Krueger is responsible for developing new biomarker applications to meet drug development needs, and provides scientific expertise needed to support sponsor-based projects across therapeutic areas. Prior to joining Invicro, Dr. Krueger was Chief Scientific Officer at Flagship Biosciences, Inc., where he led the R&D and Scientific efforts in applying novel quantitative tissue image analysis approaches to immuno-oncology and rare diseases to support drug and companion diagnostic development. Prior to Flagship Biosciences, he served in senior scientific roles in oncology drug development for OSI Pharmaceuticals in Boulder, CO and Pfizer in Andover, MA. Dr. Krueger completed his postdoctoral fellowship at The Scripps Research Institute and The University of California, San Diego after completing his Ph.D. in Cancer Biology at Wayne State University in Detroit, MI.

Amanda Bares, Ph.D.
Senior Scientist, Advanced Pathology Services

As an expert in fluorescence microscopy, multiplexed assay development, and multiplexed imaging, Dr. Bares leads many projects across various therapeutic areas requiring advanced staining and imaging approaches. Prior to joining Invicro, Dr. Bares was an R&D Senior Scientist at Ultivue, a Cambridge-based startup developing pre-optimized multiplexed immunofluorescence kits for immuno-oncology applications. There, she played a key role in choosing the fluorescent dye panels used and established kit compatibility with a variety of commercial autostainers and whole slide scanners. During her Ph.D., Dr. Bares built a hyperspectral two-photon microscope capable of acquiring in vivo multiplexed images using spectral unmixing. She completed her Ph.D. in Biomedical Engineering at Cornell University in 2017 and her Bachelor of Science in Electrical Engineering at Montana State University in 2011. 
© 2024 Invicro. All Rights Reserved